# SKB500 Combinations in Patients With Small Cell Lung Cancer

Source: https://onco.cc/trials/nct07296809/  
OnCo record `nct07296809` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of KL-A167, Carboplatin, Etoposide in small-cell lung cancer, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.

## Summary

SKB500 Combinations in Patients With Small Cell Lung Cancer is a phase 2 interventional study registered as NCT07296809 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 80 participants planned, started 2026-01-30 and due to reach its primary completion in 2028-12-31. Interventions recorded: SKB500 Powder for Injection, KL-A167 Injection, Carboplatin Injection, Etoposide Injection. Conditions listed: Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07296809
- Phase: 2
- Setting: A Phase II, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of SKB500 Combinations in Patients With Small Cell Lung Cancer
- Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT07296809: https://clinicaltrials.gov/study/NCT07296809

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Etoposide](https://onco.cc/drugs/etoposide/), [KL-A167](https://onco.cc/drugs/kl-a167/)
- companies: [Sichuan Kelun-Biotech](https://onco.cc/companies/kelun-biotech/)

---
JSON: https://onco.cc/api/v1/entities/nct07296809.json